Welcome to our dedicated page for Sage Therapeutic SEC filings (Ticker: SAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing the clinical trial nuances buried in Sage Therapeutics’ SEC disclosures can feel like decoding neuroscience itself. Cash-burn details, FDA feedback, and insider moves often span hundreds of pages, leaving investors hunting for the data that moves SAGE’s share price.
Stock Titan solves that problem. Our AI instantly converts every Sage Therapeutics quarterly earnings report 10-Q filing, annual report 10-K simplified edition, and Sage Therapeutics 8-K material events explained post into plain-English highlights. Need real-time alerts? We stream Sage Therapeutics Form 4 insider transactions real-time so you never miss executive stock transactions. Curious about dilution risk? The platform links R&D expense trends directly to clinical program updates, while our AI narrative answers common searches like “Sage Therapeutics SEC filings explained simply” and “understanding Sage Therapeutics SEC documents with AI.”
Whether you’re tracking postpartum-depression launch metrics or comparing NMDA program spend, you’ll find every filing type in one place:
- Sage Therapeutics insider trading Form 4 transactions with easy charts
- Sage Therapeutics proxy statement executive compensation details distilled
- Sage Therapeutics quarterly earnings report 10-Q filing revenue and runway tables
- Sage Therapeutics earnings report filing analysis highlighting trial milestones
Use these insights to monitor drug-approval catalysts, spot capital-raise signals, and gauge management’s confidence. Stop sifting through PDFs and start acting on knowledge the moment the filing hits EDGAR.
The Reporting Persons — Madison Avenue International LP, Madison Avenue Partners LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC and Eli Samaha — disclosed beneficial ownership of 6,077,065 shares of Sage Therapeutics common stock, representing approximately 9.7% of the 62,620,694 shares used as the basis for the calculation. The ownership is reported as shared voting and shared dispositive power, with no sole voting or dispositive power claimed.
The statement was filed on Schedule 13G, indicating a passive stake, and includes a certification that the securities were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Sage Therapeutic (SAGE)?
What is the market cap of Sage Therapeutic (SAGE)?
